

BIOARCTIC AB (PUBL)
NASDAQ STOCKHOLM: BIOA B

Third Quarter Report January-September 2020

Stockholm, October 14, 2020

Gunilla Osswald, PhD, CEO
Oskar Bosson, VP Communications & IR



Disclaimer

- This presentation has been prepared and produced by BioArctic AB (publ) (“BioArctic”) solely for the benefit of investment analysis of BioArctic and may not be used for any other purpose. Unless otherwise stated, BioArctic is the source for all data contained in this presentation. Such data is provided as at the date of this presentation and is subject to change without notice.
- This presentation includes forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause BioArctic’s actual results, performance, achievements or industry results to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date of this presentation and BioArctic expressly disclaims any obligation or undertaking to release any update of, or revisions to, any forward-looking statement in this presentation, as a result of any change in BioArctic’s expectations or any change in events, conditions or circumstances on which these forward-looking statements are based.
- This presentation does not constitute or form part of, and should not be construed as, an offer or invitation for the sale of or the subscription of, or a solicitation of any offer to buy or subscribe for, any securities, nor shall it or any part of it or the fact of its distribution form, or be relied on in connection with, any offer, contract, commitment or investment decision relating thereto, nor does it constitute a recommendation regarding the securities of BioArctic.
- The information in this presentation has not been independently verified.
- No regulatory body in Sweden or elsewhere has examined, approved or registered this presentation.

BioArctic – a unique Swedish biopharma company

Improving life for patients with central nervous system disorders



High unmet need for disease-modifying treatments for Alzheimer's and Parkinson's diseases creates **large commercial opportunity**



World-class research and development driven organization with basis in founder's breakthrough discoveries and fruitful collaborations with leading **academic researchers** and **pharma companies** generating and developing **innovative projects**



Attractive and well-balanced project portfolio with projects from discovery through Phase 3 and combination of both proprietary projects with substantial marketing and out-licensing potential and partnered projects generating income



Well-financed with approximately BSEK 1 (MUSD >100¹) in cash, **net profitable** during the last seven years and **valuable collaboration agreements** totaling BSEK 9.6² (BUSD ~1) plus royalties

1) FX as per September 30, 2020
2) FX as per December 31, 2019

Q3 2020 highlights

Another Phase 3 study in Alzheimer's disease

General

- Celebrated 3 years as a listed company

BAN2401

- Recruitment of early Alzheimer patients for Clarity AD confirmatory Phase 3 study ongoing
- Phase 2b open label extension study data presented at AAIC
 - Rapid reduction of amyloid in the brain (already at 3 months) and Consistent low level of adverse event ARIA-E (<10%)
- Phase 3 study in preclinical AD, AHEAD 3-45, started

ABBV-0805

- Recruitment to Phase 1 MAD study canceled. Detailed plan to accelerate the project into Phase 2 currently being prepared by AbbVie



Attractive and well-balanced project portfolio combines fully-financed partner projects and cutting-edge proprietary projects

	Project	Partner	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
ALZHEIMER'S DISEASE	BAN2401 (<i>Clarity AD</i>)	Eisai ¹	Early Alzheimer's disease ⁴				
	BAN2401 (<i>AHEAD 3-45</i>)	Eisai ¹	Preclinical (asymptomatic) Alzheimer's disease ⁵				
	BAN2401 back-up	Eisai					
	AD1801						
	AD1502						
	AD1503						
	AD2603						
PARKINSON'S DISEASE	ABBV-0805 ²	AbbVie					
	PD1601	AbbVie					
	PD1602	AbbVie					
OTHER CNS DISORDERS	BAN2401		Down's syndrome ³ Traumatic brain injury ³				
	ND3014						
BLOOD-BRAIN BARRIER TECHNOLOGY	BBB technology platform						
DIAGNOSTICS	Imaging and biochemical biomarkers – Alzheimer's disease						
	Imaging and biochemical biomarkers – Parkinson's disease	AbbVie					

as of September 30, 2020

1) Partnered with Eisai for BAN2401 for treatment of Alzheimer's disease. Eisai entered partnership with Biogen regarding BAN2401 in 2014

2) AbbVie in-licensed BAN0805 in late 2018 and develops the antibody with the designation ABBV-0805

3) Dementia and cognitive impairment associated with Down's syndrome and with traumatic brain injury

4) Mild cognitive impairment due to Alzheimer's disease and mild Alzheimer's disease

5) Normal cognitive function with intermediate or elevated levels of amyloid in the brain

Long-standing and extensive partnerships

Alzheimer's disease

Partner track record





Discovered and developed world's best-selling medicine for symptoms in Alzheimer's



Industry-leading pipeline in dementia area

Collaboration and license



- BioArctic retains rights to BAN2401 in other indications and option to market in the Nordics

Parkinson's disease

Partner track record



World's all-time best-selling medicine (BUSD 20)





10 different indications in immunology

Approved product for symptoms associated with Parkinson's disease



Collaboration and license



- AbbVie global rights to alpha-synuclein portfolio for all indications

Sources: Eisai, AbbVie and BioArctic corporate information

BAN2401: potential disease modifying antibody for Alzheimer's disease with positive Phase 2b results now in Phase 3

High unmet medical need

No existing disease-modifying treatment



**IN 20
YEARS**
doubling

TODAY

>30 million
people with Alzheimer's

BAN2401 unique profile

Unique and targeted binding profile

- Highly selective for toxic forms of misfolded Abeta (oligomers/protofibrils)


Unique clinical fingerprint

- Rapid onset of clinical effect
- Consistent effects
- No titration required due to low frequency of ARIA-E

BAN2401 has positive Phase 2b results

- **Large trial:** 856 early Alzheimer's patients
- **Consistent effects** on clinical outcomes, imaging and neurodegenerative biomarkers
- **Effect increase over time**
- **Good safety profile**

Broad BAN2401 clinical program – driven by BioArctic’s partner Eisai



ABBV-0805: potential disease modifying antibody for Parkinson's disease with strong preclinical results now in Phase 1

High unmet medical need

No existing disease-modifying treatment



Younger patient group, still at working age

TODAY

>6 million¹ people with Parkinson's

Unique profile

Unique and targeted binding profile


- Highly selective for toxic forms of misfolded alpha-synuclein (oligomers/protofibrils)

Built on genetic and pathology rationale


- Alpha-synuclein mutations lead to Parkinson's
- Alpha-synuclein oligomers/protofibrils are elevated in Parkinson's

Preclinical proof of concept

Reduction of neurotoxic alpha-synuclein oligomers/protofibrils



Delays disease progression and increases lifespan




1) Dorsey and Bloem, JAMA Neurology 2018;75:9-10

Continued progress in collaboration with AbbVie on alpha-synuclein

Collaboration highlights


- ABBV-0805 targeting disease modification in Parkinson's disease
- Potential to expand to earlier stage Parkinson's disease patients and other diseases where alpha-synuclein plays a role
- AbbVie is responsible for clinical development
- BioArctic is responsible for delivering follow-up antibodies in the continued collaboration with AbbVie

ABBV-0805 advancing in clinical trials



Early stage portfolio continues to develop well

Alzheimer's disease



Discovery stage programs

- 4 fully-owned disease modifying antibody projects in Alzheimer's disease
- Each project has a different mechanism from the others

Parkinson's disease




Discovery stage projects

- Preclinical stage alpha-synuclein projects in research collaboration with

abbvie


Other CNS disorders



Neurodegeneration research

- BAN2401 in indications other than Alzheimer's disease
- Research project in neurodegeneration ("ND") with potential in various CNS disorders

Blood-brain barrier technology



Blood-brain barrier technology platform

- Continued development with expanded and enhanced capabilities
- Collaboration with Uppsala University under Vinnova grant

Diagnostics




Diagnostics

- Continued development of imaging and biochemical biomarkers



Financial Summary

Net revenues and operating profit Q3 2020




- Net revenues were 11 MSEK (21) for the third quarter
- The change is mainly related to lower activity for BioArctic in the Parkinson's program, according to plan

- Lower currency exchange losses and travel costs
- Project expenses in total decreased to 11 MSEK (13) in the third quarter, while project expenses in our own projects increased in Q3 compared to the previous year due to higher activity

- Operating profit was -21 MSEK (-11) for the third quarter
- The change is mainly attributable to lower activity for BioArctic in the Parkinson's program, according to plan

Operating expenses are expected to be in the range of 150 - 170 MSEK for the financial year January - December 2020

Cash and net profit Q3 2020



- Cash balance amounted to 1,036 MSEK (1,170) at the end of the third quarter

- Operating cash flow amounted to -9 MSEK (-49) during Q3

- Net result for the period was -21 MSEK (-8)
- The change is mainly attributable to lower activity for BioArctic in the Parkinson's program, according to plan

In summary, BioArctic continues to have a strong financial position



**Upcoming news and
closing remarks**

Upcoming news flow

Alzheimer's disease



BAN2401 (Eisai)

- To present data at international congresses
- Phase 3 confirmatory study in early AD results 2022
- Phase 2b open label extension study results
- Phase 3 study in preclinical AD

Discovery stage programs

- Advance into preclinical development

Parkinson's disease




ABBV-0805 (AbbVie)

- Complete Phase 1 and start Phase 2

Discovery stage projects

- Development in AbbVie collaboration


Other CNS disorders



Neurodegeneration research

- New project development
- New indications and new targets

Blood-brain barrier technology



Blood-brain barrier technology platform

- Continue development of platform

Diagnostics



Diagnostics

- Continue development of imaging and biochemical biomarkers

BioArctic: With Patients in Mind

Built on science



Great science

Projects in focus

	Project	Partner	Discovery	Preclinical	Phase 1	Phase 2	Phase 3
ALZHEIMER'S DISEASE	BAN2401 (Clarity AD)	Eisai ¹	Early Alzheimer's disease ²				
	BAN2401 (AHEAD 3-45)	Eisai ¹	Preclinical (asymptomatic) Alzheimer's disease ²				
	BAN2401 back-up	Eisai ¹					
	AD1801						
	AD1502						
	AD1503						
PARKINSON'S DISEASE	AD2603						
	ABV-0805 ²	AbbVie					
	PD1801	AbbVie					
	PD1802	AbbVie					
OTHER CNS DISORDERS	BAN2401		Open's syndrome ²				
	ND3014		Traumatic brain injury ²				
BLOOD-BRAIN BARRIER TECHNOLOGY	BBB technology platform						
DIAGNOSTICS	Imaging and biochemical biomarkers - Alzheimer's disease						
	Imaging and biochemical biomarkers - Parkinson's disease	AbbVie					

Great projects

Value-driven leadership



Great people

GUNILLA OSSWALD, CEO



JAN MATTSSON, CFO



**OSKAR BOSSON, VP
COMMUNICATIONS & IR**



**NEXT REPORT & IR
CONTACT**

- **Next Report:**
Full year report Jan-Dec
2020 on February 4, 2021
- **Contact:**
Oskar Bosson,
VP Communications & IR
+46 704 10 71 80
ir@bioarctic.se

To subscribe to financial reports/press releases and for more information, please visit www.bioarctic.com